Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway

Abstract Background Thirty to 40 % of non-small cell lung cancer (NSCLC) patients developed higher hypertriglyceridemia in the process of treatment with bexarotene. And bioinformatics studies discovered that the expression of slc10a2 was increased in high-grade hypertriglyceridemia patients. So, we...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Xinghao Ai, Feng Mao, Shengping Shen, Yang Shentu, Jiejun Wang, Shun Lu
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	BMC 2018-04-01
Serie:	BMC Cancer
Ämnen:	Non-small cell lung cancer A549 cells H1299 cells Bexarotene slc10a2 PPARγ
Länkar:	http://link.springer.com/article/10.1186/s12885-018-4224-x
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!